# Bullous Pemphigoid

Confirm bullous pemphigoid with perilesional direct immunofluorescence plus serology, assess extent and mucosal disease, and select treatment by disease control needs against corticosteroid toxicity in an often frail older population.

**Clinical question:** How should clinicians confirm bullous pemphigoid and choose initial treatment while minimizing treatment-related harm?

Updated: 2026-09-15T23:15:48.142723+00:00

## What matters in practice
- Obtain perilesional skin for direct immunofluorescence and pair it with serum BP180/BP230 testing and/or indirect immunofluorescence when BP is suspected; no single assay excludes disease reliably. [22][24]
- Direct immunofluorescence showing linear IgG and/or C3 along the dermoepidermal junction supports BP, but salt-split indirect immunofluorescence and BP180/BP230 serology help resolve diagnostic uncertainty. [23][24]
- Prednisolone 0.5 mg/kg/day produced more rapid 6-week disease control than doxycycline 200 mg/day, but systemic corticosteroid exposure carries substantial morbidity in the typical older BP population. [7][11][15]
- For adults, FDA-labeled dupilumab dosing is 600 mg once followed by 300 mg subcutaneously every 2 weeks, used with a tapering oral corticosteroid course until disease control, then continued as monotherapy. [1][3]
- Reassess disease control early: in a 146-patient retrospective cohort, 87% receiving dupilumab achieved disease control within 4 weeks; delayed control beyond 4 weeks occurred in 5.5%. [8]

## Confirm BP before committing to prolonged immunosuppression

Use lesional morphology to guide biopsy placement, then confirm an autoimmune subepidermal blistering disorder immunopathologically.

For a patient with tense bullae, erosions, or a persistent pruritic urticarial or eczematous eruption suspicious for BP, obtain a perilesional biopsy for direct immunofluorescence (DIF). Sample erythematous perilesional skin rather than the bulla itself and place the specimen in Michel medium. A supportive pattern is linear IgG and/or C3 at the dermoepidermal junction. [24]

Order serum anti-BP180 and anti-BP230 IgG ELISAs and consider indirect immunofluorescence (IIF), particularly on salt-split skin, at initial evaluation. In one comparative study, DIF sensitivity was 90.8% and specificity 98%; combined serologic testing had 88.8% sensitivity. Thus, a negative BP180 or BP230 ELISA alone should not overrule a compatible clinical presentation or a positive DIF. [22]

Salt-split IIF is most useful when DIF or ELISA findings are discordant with morphology or when another autoimmune subepidermal blistering disorder remains plausible. Reported specificity for salt-split IIF was 99.9%, while BP180 NC16A ELISA sensitivity and specificity were 70.0% and 89.8%, respectively, in a consensus evidence summary. [24]
- Classical diagnostic phenotype: age older than 70 years, no atrophic scars, no mucosal involvement, and no predominant head or neck bullae; confirm with linear junctional IgG/C3 on DIF plus anti-basement-membrane-zone antibodies by IIF and/or anti-BP180/BP230 antibodies. [24]
- Nonclassical disease may present with pruritus and urticarial or eczematous lesions before frank bullae; use the same DIF and serologic confirmation strategy rather than waiting for widespread blistering. [24]
- Interpret DIF as a high-value confirmatory test, not an isolated disease label: linear junctional deposition can occur in other acquired autoimmune subepidermal blistering diseases. [23]

*Diagnostic assay performance and the clinical role of each test in suspected bullous pemphigoid. [22][23][24]*

| Test | Supportive result | Reported performance | What the result changes |
| --- | --- | --- | --- |
| Perilesional DIF | Linear IgG and/or C3 at the dermoepidermal junction | Sensitivity 90.8%; specificity 98% in one comparative study. [22] | Primary tissue confirmation; if negative but suspicion remains high, pursue serology and salt-split IIF rather than excluding BP. [22][24] |
| IIF on salt-split skin | Circulating anti-basement-membrane-zone antibodies | Specificity 100% in one comparative study; summarized sensitivity 77.0% and specificity 99.9%. [22][24] | Clarifies discordant testing and supports diagnosis when distinguishing autoimmune subepidermal blistering disease is necessary. [23][24] |
| BP180 NC16A ELISA | Anti-BP180 IgG | Sensitivity 72.0%; specificity 94.1% in one study; summary sensitivity 70.0% and specificity 89.8%. [22][24] | Supports diagnosis but does not independently exclude BP when negative. [22] |
| BP230 ELISA | Anti-BP230 IgG | Sensitivity 59.0%; specificity 99.2% in one study; summary sensitivity 44.6% and specificity 92.8%. [22][24] | Adds diagnostic yield alongside BP180 and DIF; limited sensitivity makes a negative result nondiagnostic. [22][24] |

## Identify factors that alter urgency and treatment risk

Treatment choice is driven by disease control requirements and vulnerability to corticosteroid complications.

Document extent of blisters and erosions, active urticarial or eczematous inflammation, itch severity, mucosal involvement, and functional effects before treatment. BPDAI erosion/blister, urticaria/erythema, mucosal, and itch measures were responsive to therapy in a retrospective treatment comparison and can provide a reproducible baseline for subsequent reassessment. [10]

Perform a medication review at diagnosis. DPP-4 inhibitor labeling includes bullous pemphigoid among recognized warnings and precautions for saxagliptin-containing products; a temporally plausible exposure should be identified as a potentially modifiable contributor while diagnostic confirmation proceeds. [4]

Weigh systemic corticosteroid exposure particularly carefully in older or medically complex patients. Long-term high-dose systemic corticosteroids contribute to increased morbidity and mortality, with recognized risks including severe infection, hyperglycemia, hypertension, osteoporosis, myopathy, neurocognitive effects, thromboembolic complications, and gastrointestinal ulceration. [11][15]

Use mucosal disease as an escalation signal. In a retrospective study of dupilumab, BPDAI mucosal scores did not significantly improve despite improvement in other clinical measures; persistent mucosal involvement therefore warrants prompt reassessment of diagnosis and treatment adequacy rather than assuming cutaneous response establishes full control. [10]
- Record baseline BP180 and BP230 titers when obtained for diagnosis; these were among laboratory parameters followed in treatment cohorts. [8][10]
- Record peripheral eosinophil count when assessing inflammatory burden or response; eosinophil count and percentage declined in corticosteroid-containing treatment groups in one retrospective study. [10]
- If systemic corticosteroids are selected, define a taper plan once control occurs rather than continuing an indefinite high-dose course. [1][11]

*Clinical findings that should change the next treatment decision in bullous pemphigoid. [1][4][10][11][15]*

| Finding | Clinical implication | Next action |
| --- | --- | --- |
| Extensive active bullae, erosions, or rapidly progressive disease | Greater need for prompt disease control. [7] | Choose a regimen with faster expected control and reassess early for ongoing new blister formation. [7][8] |
| High risk from systemic corticosteroids | Steroid toxicity may outweigh the benefit of rapid control from a systemic steroid-first strategy. [7][11][15] | Discuss a steroid-sparing approach or FDA-labeled dupilumab with a corticosteroid taper when appropriate. [1][7] |
| Saxagliptin or another DPP-4 inhibitor exposure | Drug-associated BP is a relevant consideration because bullous pemphigoid is included in DPP-4 inhibitor safety warnings. [4] | Review timing and coordinate diabetes therapy modification with the prescribing clinician. [4] |
| Persistent mucosal disease despite improving skin lesions | May represent incomplete control or a diagnostic mismatch. [10][23] | Reevaluate immunopathology, serology, and treatment strategy promptly. [10][23] |

## Choose initial therapy by the speed-versus-toxicity tradeoff

No initial regimen is risk-free; select for clinical control while minimizing cumulative systemic corticosteroid exposure.

For patients requiring prompt control, prednisolone 0.5 mg/kg/day achieved disease control at 6 weeks in 91% of participants in a randomized trial, compared with 74% for doxycycline 200 mg/day. The adjusted difference was 18.6 percentage points, favoring prednisolone for short-term effectiveness. [7]

Doxycycline 200 mg/day is a reasonable initial lower-toxicity strategy when slower or less complete early control is acceptable and systemic corticosteroid harm is a dominant concern. In the same randomized comparison, the key tradeoff was lower 6-week control than prednisolone, while the study was designed to assess whether doxycycline reduced severe treatment-related adverse effects. [7]

For adults with BP, dupilumab is FDA labeled as a 600 mg subcutaneous loading dose followed by 300 mg subcutaneously every 2 weeks. The label directs use with a tapering course of oral corticosteroids; after disease control, gradually taper corticosteroids and continue dupilumab monotherapy. Add corticosteroids again for relapse if medically advisable. [1][3]

Dupilumab should not be positioned as a guarantee of immediate remission. In a retrospective cohort of 146 patients, 127 patients (87%) achieved disease control within 4 weeks, while 8 patients (5.5%) reached disease control after 4 weeks. Use active disease tracking during the first month to identify continued blistering that requires treatment reassessment. [8]
- Prednisolone strategy studied: 0.5 mg/kg/day orally; superior 6-week disease control versus doxycycline, but systemic corticosteroid toxicity is clinically consequential. [7][11]
- Doxycycline strategy studied: 200 mg/day orally; less effective for 6-week control than prednisolone in the randomized trial. [7]
- Adult dupilumab strategy: 600 mg subcutaneously once, then 300 mg subcutaneously every 2 weeks; pair initially with tapering oral corticosteroids. [1][3]
- Avoid allowing apparent control to become unmonitored maintenance: systemic corticosteroid duration and dose materially influence morbidity and mortality risk. [11][15]

### Topical versus systemic corticosteroid exposure

When corticosteroid therapy is being considered, distinguish feasibility of extensive topical treatment from systemic exposure. A 2024 comparative cohort found topical corticosteroid treatment may have a lower risk of death than systemic corticosteroid treatment, although it was associated with a heightened relapse risk and requires prospective validation. [9]

Use that tradeoff in shared treatment planning: topical therapy may be favored when application logistics are achievable and avoiding systemic toxicity is paramount; systemic therapy may still be selected when disease-control urgency or treatment practicality outweighs that potential advantage. [7][9]

*Initial systemic treatment options supported by the cited studies and FDA labeling. [1][3][7][8]*

| Strategy | Dose studied or labeled | Best fit | Principal limitation |
| --- | --- | --- | --- |
| Prednisolone | 0.5 mg/kg/day orally in the randomized trial. [7] | Need for the greatest likelihood of early disease control. [7] | Systemic corticosteroid-related morbidity is substantial, especially with prolonged or high-dose exposure. [11][15] |
| Doxycycline | 200 mg/day orally in the randomized trial. [7] | Patients in whom reducing systemic corticosteroid exposure is prioritized and less rapid initial control is acceptable. [7] | Lower 6-week disease control than prednisolone: 74% versus 91%. [7] |
| Dupilumab plus tapering oral corticosteroid | 600 mg subcutaneously once, then 300 mg subcutaneously every 2 weeks in adults. [1][3] | Adults for whom FDA-labeled biologic treatment with a corticosteroid-sparing plan is appropriate. [1][3] | Early response is not universal; 5.5% achieved control only after 4 weeks in a retrospective cohort. [8] |

## Monitor active disease and adjust therapy when control is not achieved

Follow the lesions that determine disease control, not itch improvement alone.

At each early follow-up, document new blisters and erosions, healing of prior erosions, urticarial or eczematous activity, itch, and mucosal involvement using the same baseline measures. In dupilumab-treated patients, BPDAI total, erosion/blister, urticaria/erythema, and itch scores improved within 2 to 4 weeks in one retrospective study, making this interval a pragmatic window for verifying a directional response. [10]

If disease remains active beyond the expected early control interval, first verify diagnosis and treatment execution: review DIF site quality, BP180/BP230 results, and whether salt-split IIF is needed. Then reassess corticosteroid risk, ongoing medication exposures, mucosal disease, and whether escalation to a steroid-sparing regimen is warranted. [22][23][24]

For dupilumab-treated adults, taper oral corticosteroids only after disease control and continue dupilumab monotherapy thereafter per labeling. If relapse occurs, oral corticosteroids may be re-added when medically advisable; this is a treatment decision requiring renewed assessment of cumulative steroid harm. [1][3]

For difficult-to-control disease, biologic approaches beyond dupilumab have been reported, including rituximab, omalizumab, and mepolizumab, but the evidence base summarized in systematic reviews is heterogeneous. Rituximab reports include infection and septicemia among serious adverse events in autoimmune bullous disease cohorts; reserve such approaches for specialist-directed management after confirmation of the disease category and careful infection-risk assessment. [11][12][13]
- At 2 to 4 weeks, persistent new blister formation or worsening mucosal disease should trigger a treatment and diagnostic reassessment. [8][10]
- Before escalating immunosuppression after a negative or equivocal initial test, repeat the diagnostic pathway with properly sampled perilesional DIF and complementary serology/IIF. [22][24]
- During any ongoing systemic corticosteroid course, actively seek complications that may necessitate steroid reduction or withdrawal, including infection, hyperglycemia, hypertension, myopathy, neurocognitive effects, osteoporosis, and thromboembolic complications. [11]

*Response-based actions during treatment of bullous pemphigoid. [1][3][8][10][22][24]*

| Follow-up finding | Interpretation | Next action |
| --- | --- | --- |
| Improvement in blister/erosion burden and itch by 2 to 4 weeks | Compatible with an early response observed in retrospective dupilumab treatment data. [10] | Continue the selected regimen and, with dupilumab, taper oral corticosteroids only after disease control. [1][3] |
| No disease control by 4 weeks on dupilumab-containing treatment | Not necessarily treatment failure, but delayed control occurred in only 5.5% of one cohort. [8] | Reassess active disease severity, diagnostic confirmation, adherence, medication triggers, and need for regimen modification. [8][22][24] |
| Cutaneous improvement with persistent mucosal involvement | Mucosal BPDAI did not significantly improve in one retrospective dupilumab monotherapy group. [10] | Reconsider diagnosis and intensify specialist-directed assessment rather than relying on cutaneous response alone. [10][23] |
| Relapse after corticosteroid taper during dupilumab treatment | FDA labeling permits corticosteroid re-addition if medically advisable. [1][3] | Reintroduce corticosteroids only after balancing relapse severity against cumulative corticosteroid risk. [1][11][15] |

## References
1. [PDF] Page 1 of 77 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf
2. NDA/BLA Multi-Disciplinary Review and Evaluation — www.fda.gov — https://www.fda.gov/media/194749/download
3. [PDF] DUPIXENT® (dupilumab) injection, for subcutaneous use — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761055s070lbl.pdf
4. [PDF] Clinical Review: Onglyza (saxagliptin)/Kombiglyze XR (saxagliptin ... — www.fda.gov — https://www.fda.gov/media/185486/download
5. [PDF] Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula ... - FDA — www.fda.gov — https://www.fda.gov/media/168233/download
6. [PDF] CENTER FOR DRUG EVALUATION AND RESEARCH — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761097Orig1s003.pdf
7. Doxycycline: a first-line treatment for bullous pemphigoid? - The Lancet — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30549-4/fulltext
8. Evaluation of Dupilumab in Patients With Bullous Pemphigoid — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2808114
9. Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids | British Journal of Dermatology | Oxford Academic — academic.oup.com — https://academic.oup.com/bjd/article-abstract/191/4/539/7682494
10. Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0365059624002496
11. Immunosuppressive therapy for autoimmune bullous diseases — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0738081X11000897
12. Efficacy and safety of biological agents for pemphigoid: a systematic review and meta‐analysis - Lin - 2023 - International Journal of Dermatology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ijd.16678?af=R
13. Exacerbation of bullous pemphigoid after hand, foot, and mouth disease treated with rituximab — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2352512615001848
14. Infectious complications in bullous pemphigoid: An analysis of risk factors - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962215000948
15. Treatment of bullous pemphigoid with methotrexate is associated ... — academic.oup.com — https://academic.oup.com/bjd/article/193/2/345/8124951
16. Mortality risk and causes of death in exogenous Cushing's ... — academic.oup.com — https://academic.oup.com/jcem/article/111/6/1765/8539558
17. British Association of Dermatologists' guidelines for the ... — academic.oup.com — https://academic.oup.com/bjd/article-pdf/175/1/23/47554078/bjd0023.pdf
18. Organ-specific eosinophilic disorders of the skin, lung, and ... — www.jacionline.org — https://www.jacionline.org/article/S0091-6749(10)00286-1/fulltext
19. Diagnosis and treatment of atopic dermatitis in children and adults — www.jacionline.org — https://www.jacionline.org/article/S0091-6749(06)00925-0/fulltext
20. Comprehensive overview of autoantibody isotype and subclass ... — www.jacionline.org — https://www.jacionline.org/article/S0091-6749%2822%2900845-4/fulltext
21. Online Exams - Journal of Allergy and Clinical Immunology — www.jacionline.org — https://www.jacionline.org/cme/home
22. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/23969034
23. Diagnostic values of indirect immunofluorescence using salt-split skin, direct immunofluorescence and BP180 NC16A ELISA on bullous pemphigoid - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9433058
24. Navigating Bullous Pemphigoid: Consensus Recommendations for ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12686190

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.